AU2005259381A1 - Nucleic acids for the treatment of HMGB1-related pathologies - Google Patents

Nucleic acids for the treatment of HMGB1-related pathologies Download PDF

Info

Publication number
AU2005259381A1
AU2005259381A1 AU2005259381A AU2005259381A AU2005259381A1 AU 2005259381 A1 AU2005259381 A1 AU 2005259381A1 AU 2005259381 A AU2005259381 A AU 2005259381A AU 2005259381 A AU2005259381 A AU 2005259381A AU 2005259381 A1 AU2005259381 A1 AU 2005259381A1
Authority
AU
Australia
Prior art keywords
nucleic acid
hmgb1
double
molecule
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005259381A
Other languages
English (en)
Inventor
Domenico G. Barone
Marco E. Bianchi
Enrico M. Bucci
Silvano Fumero
Domenica Musumeci
Roberto Sapio
Margherita Valente
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creabilis Therapeutics SpA
Original Assignee
Creabilis Therapeutics SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005259381(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Creabilis Therapeutics SpA filed Critical Creabilis Therapeutics SpA
Publication of AU2005259381A1 publication Critical patent/AU2005259381A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005259381A 2004-07-02 2005-07-04 Nucleic acids for the treatment of HMGB1-related pathologies Abandoned AU2005259381A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58467804P 2004-07-02 2004-07-02
US60/584,678 2004-07-02
US64658605P 2005-01-26 2005-01-26
US60/646,586 2005-01-26
PCT/EP2005/007198 WO2006002971A2 (en) 2004-07-02 2005-07-04 Nucleic acids for the treatment of hmgb1-related pathologies

Publications (1)

Publication Number Publication Date
AU2005259381A1 true AU2005259381A1 (en) 2006-01-12

Family

ID=35106975

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005259381A Abandoned AU2005259381A1 (en) 2004-07-02 2005-07-04 Nucleic acids for the treatment of HMGB1-related pathologies

Country Status (14)

Country Link
US (1) US20080305073A1 (https=)
EP (1) EP1768677B1 (https=)
JP (1) JP2008504335A (https=)
AT (1) ATE399014T1 (https=)
AU (1) AU2005259381A1 (https=)
BR (1) BRPI0512944A (https=)
CA (1) CA2572519A1 (https=)
DE (1) DE602005007746D1 (https=)
DK (1) DK1768677T3 (https=)
ES (1) ES2306195T3 (https=)
IL (1) IL179828A0 (https=)
PL (1) PL1768677T3 (https=)
PT (1) PT1768677E (https=)
WO (1) WO2006002971A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5188804B2 (ja) 2004-08-03 2013-04-24 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
KR20080105066A (ko) * 2006-02-09 2008-12-03 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
JP3882090B1 (ja) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
CN101589309A (zh) * 2006-11-17 2009-11-25 临床基因网络公司 涉及基因gypc、agpat3、agl、pvrl2、hmgb3、hsdl2和/或ldb2的筛选和治疗方法
US20100056608A1 (en) * 2006-11-17 2010-03-04 Clinical Gene Networks Ab Methods for screening and treatment involving the genes gypc, agpat3, agl, pvrl2, hmgb 3, hsdl2 and/or ldb2
US8927510B2 (en) 2008-05-16 2015-01-06 Children's Medical Center Corporation Compositions and methods for inhibition of retroviruses
WO2009149921A2 (en) * 2008-06-11 2009-12-17 Bionucleon S.R.L. Inhibition of hrp-3 using modified oligonucleotides
DK2329266T3 (en) 2008-09-11 2016-07-18 Pasteur Institut MONITORING AND INHIBITING INFECTION WITH HUMAN IMMUNE DEFECT VIRUS BY MODULATING HMGB1-DEPENDENT TRACTOR OF HIV-1 REPLICATION AND PERSISTENCE
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
PT2381964E (pt) 2008-12-22 2014-08-29 Creabilis S A Síntese de conjugados poliméricos de compostos de indolocarbazol
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
GB0911569D0 (en) * 2009-07-03 2009-08-12 Ulive Entpr Ltd Method for the detection of organ or tissue injury
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
US8975019B2 (en) * 2009-10-19 2015-03-10 University Of Massachusetts Deducing exon connectivity by RNA-templated DNA ligation/sequencing
WO2012036215A1 (ja) 2010-09-17 2012-03-22 Taniguchi Tadatsugu Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
US20140378531A1 (en) * 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
JP6624542B2 (ja) * 2015-02-05 2019-12-25 国立大学法人広島大学 ヒトｈｍｇｂ１結合剤およびヒトｈｍｇｂ１除去装置
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175315A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates of staurosporine derivatives having reduced exposure
WO2018175301A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugate of montesanib with reduced exposure
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
EP3621657A1 (en) 2017-05-10 2020-03-18 Sienna Biopharmaceuticals, Inc. Uses of polymer conjugates of indolocarbazole compounds with reduced exposure
CN111304202B (zh) * 2020-02-26 2023-03-28 西安交通大学 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用
CN114957440A (zh) * 2022-05-26 2022-08-30 江苏大学 一种重组HMGB1 A Box蛋白及其获取方法与应用
EP4543459A1 (en) * 2022-06-23 2025-04-30 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Hmgb1 inhibitors for treatment of apoe4-related tauopathies including alzheimer's disease
CN114807150B (zh) * 2022-06-28 2022-10-14 中国科学院基础医学与肿瘤研究所(筹) 靶向和拮抗hmgb1分子的核酸适体
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性ｄｎａベクター
CN115774004B (zh) * 2022-08-19 2024-07-05 四川大学华西医院 二氧化锆@量子点复合微球在制备检测hmgb1的荧光探针中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672188B1 (en) * 1992-10-14 2003-12-10 NeXstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CA2506328A1 (en) * 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents

Also Published As

Publication number Publication date
JP2008504335A (ja) 2008-02-14
EP1768677A2 (en) 2007-04-04
CA2572519A1 (en) 2006-01-12
DE602005007746D1 (de) 2008-08-07
PL1768677T3 (pl) 2009-01-30
PT1768677E (pt) 2008-10-06
EP1768677B1 (en) 2008-06-25
ES2306195T3 (es) 2008-11-01
BRPI0512944A (pt) 2008-04-15
WO2006002971A2 (en) 2006-01-12
ATE399014T1 (de) 2008-07-15
IL179828A0 (en) 2008-03-20
DK1768677T3 (da) 2008-10-20
US20080305073A1 (en) 2008-12-11
WO2006002971A3 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
EP1768677B1 (en) Nucleic acids for the treatment of hmgb1-related pathologies
US7635679B2 (en) Protease resistant mutant of human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A)
US11208663B2 (en) Post-selex modification methods
US9707298B2 (en) Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
US20090191253A2 (en) Use of K-252a and Kinase Inhibitors for the Prevention or Treatment of HMGB1-Associated Pathologies
JP2012512170A (ja) 血管バリア機能の促進および肺線維症の治療する組成物および方法
JP6566947B2 (ja) Ｍａｐキナーゼｐ３８結合化合物
Penolazzi et al. Peptide nucleic acid-DNA decoy chimeras targeting NF-κB transcription factors: Induction of apoptosis in human primary osteoclasts
WO2015050957A2 (en) Treatments for systemic lupus erythematosus
KR20250166123A (ko) 신경계 복구를 위한 단백질 티로신 포스파타제 웨지 도메인 펩티드 이량체
FINOTTI et al. Peptide nucleic acid-DNA decoy chimeras targeting NF-KB transcription factors: Induction of apoptosis in human primary osteoclasts
HK1134779B (en) Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
HK1204014B (en) Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application